Antibiotic resistance of bacteria in biofilms, Lancet, vol.358, issue.9276, pp.135-138, 2001. ,
Biofilms: survival mechanisms of clinically relevant microorganisms, Clin Microbiol Rev, vol.15, issue.2, pp.167-93, 2002. ,
In vitro emergence of high persistence upon periodic aminoglycoside challenge in the ESKAPE pathogens, Antimicrob. Agents Chemother, p.4630, 2016. ,
Extracellular matrix structure governs invasion resistance in bacterial biofilms, ISME J, vol.9, p.1700, 2015. ,
The biofilm matrix, Nat. Rev. Microbiol, vol.2010, issue.9, pp.623-656 ,
Antimicrobial tolerance and the significance of persister cells in recalcitrant chronic wound biofilms. Wound repair and regeneration, vol.19, pp.1-9, 2011. ,
Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis, J. Bacteriol, issue.23, pp.6191-6200, 2010. ,
Stratified growth in Pseudomonas aeruginosa biofilms, Appl. Environ. Microbiol, vol.70, issue.10, pp.6188-96, 2004. ,
Emergent bacteria in cystic fibrosis: in vitro biofilm formation and resilience under variable oxygen conditions, BioMed Res. Int, p.678301, 2014. ,
Cystic fibrosis pathogenesis and the role of biofilms in persistent infection, Trends Microbiol, vol.9, issue.2, pp.50-52, 2001. ,
Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection, Am. J. Respir. Crit. Care Med, vol.189, issue.7, pp.1-58, 2014. ,
Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections, Curr. Top. Med. Chem, issue.16, pp.1552-76, 2015. ,
Anaerobic physiology of Pseudomonas aeruginosa in the cystic fibrosis lung, Int. J. Med. Microbiol, issue.8, pp.549-56, 2010. ,
Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung, Journal of bacteriology, vol.191, issue.11, pp.3492-3503, 2009. ,
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis, Cell, vol.63, issue.4, pp.827-834, 1990. ,
Pathogenesis of the pseudomonas lung lesion in cystic fibrosis, Chest, vol.96, issue.1, pp.158-64, 1989. ,
Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients, PLoS One, vol.5, issue.6, p.11044, 2010. ,
Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients, Pediatr Pulmonol, vol.44, issue.6, pp.547-58, 2009. ,
Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines, C. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection, Ann. Am. Thorac. Soc, vol.11, issue.10, pp.1640-50, 2014. ,
Management of pulmonary disease in patients with cystic fibrosis, N. Engl. J. Med, vol.335, issue.3, pp.179-88, 1996. ,
Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis, Am. J. Respir. Crit. Care Med, vol.162, issue.2, pp.481-486, 2000. ,
Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease, Pediatr Pulmonol, vol.38, issue.4, pp.314-320, 2004. ,
Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms, Antimicrob. Agents Chemother, vol.2013, issue.5, pp.2352-61 ,
Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa, Antimicrob. Agents Chemother, vol.42, issue.4, pp.518-523, 1988. ,
The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin, Environ. Microbiol, vol.15, issue.10, pp.2865-2878, 2013. ,
Measuring mucociliary transport and mucus properties in multiple regions of airway epithelial surfaces helps clarify cystic fibrosis defects, Paediatric respiratory reviews, vol.3, issue.2, pp.115-119, 2002. ,
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Delivery Rev, vol.61, issue.2, pp.158-171, 2009. ,
Drug diffusion through cystic fibrotic mucus: Steady-state permeation, rheologic properties, and glycoprotein morphology, J. Pharm. Sci, vol.85, issue.6, 1996. ,
Improved Biofilm Antimicrobial Activity of Polyethylene Glycol Conjugated Tobramycin Compared to Tobramycin in Pseudomonas aeruginosa, Biofilms. Mol. Pharmaceutics, vol.12, issue.5, pp.1544-53, 2015. ,
Synthesis of tolerogenic monomethoxypolyethylene glycol and polyvinyl alcohol conjugates of peptides, J. Protein Chem, vol.10, issue.6, pp.623-627, 1991. ,
Proton NMR characterization of poly (ethylene glycols) and derivatives. Macromolecules, vol.23, pp.3742-3746, 1990. ,
Monofunctional Poly(ethy1ene glycol): Characterization and Purity for Protein-Modification Applications, Chemical Aspects of Drug Delivery Systems ,
Zero-Length Crosslinkers, Bioconjugate Techniques, vol.178, 1996. ,
, , pp.215-233, 2008.
Dextrin?Colistin Conjugates as a Model Bioresponsive Treatment for Multidrug Resistant Bacterial Infections, Mol. Pharmaceutics, vol.11, issue.12, pp.4437-4447, 2014. ,
Assignments of the 1H-and 13C-nmr spectra of tobramycin at low and high pH, Carbohydr. Res, vol.170, issue.1, pp.1-17, 1987. ,
Sound waves effectively assist tobramycin in elimination of Pseudomonas aeruginosa biofilms in vitro, AAPS PharmSciTech, vol.15, issue.6, pp.1644-54, 2014. ,
Bacterial lipopolysaccharides variably modulate in vitro biofilm formation of Candida species, J. Med. Microbiol, vol.59, pp.1225-1259, 2010. ,
Determination of minimum inhibitory concentrations, J. Antimicrob. Chemother, vol.48, pp.5-16, 2001. ,
Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung, J. Med. Microbiol, vol.54, issue.7, pp.667-676, 2005. ,
Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum, Proc. Natl. Acad. Sci. U. S. A, vol.112, issue.13, pp.4110-4115, 2015. ,
Gene expression of Pseudomonas aeruginosa in a mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum, J. Med. Microbiol, vol.59, issue.9, pp.1089-1100, 2010. ,
A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms, Proc. Natl. Acad. Sci. U. S. A, issue.48, pp.18131-18136, 2006. ,
DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase, Thorax, vol.50, issue.8, pp.880-882, 1995. ,
Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa, Can. J. Microbiol, vol.43, issue.11, pp.999-1004, 1997. ,
The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa, J. Med. Microbiol, vol.45, issue.2, pp.110-119, 1996. ,
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions, J. Clin. Invest, vol.116, issue.2, p.436, 2006. ,
Validation of drop plate technique for bacterial enumeration by parametric and nonparametric tests, Vet Res. Forum, vol.2013, issue.3, pp.179-183 ,
The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum, Eur. Respir. J, vol.3, issue.1, pp.19-23, 1990. ,
Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus, Eur. Respir. J, vol.8, issue.3, pp.381-386, 1995. ,
Mucus structure and properties in cystic fibrosis. Paediatric respiratory reviews, vol.8, pp.4-7, 2007. ,
Gentamicin and leucine inhalable powder: what about antipseudomonal activity and permeation through cystic fibrosis mucus?, Int. J. Pharm, vol.440, issue.2, pp.250-255, 2013. ,
Physicochemical properties of mucus and their impact on transmucosal drug delivery, Int. J. Pharm, vol.2017, issue.1, pp.555-572 ,
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus, Proc. Natl. Acad. Sci. U. S. A, vol.104, issue.5, pp.1482-1487, 2007. ,
The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles, Biomaterials, vol.30, issue.13, pp.2591-2597, 2009. ,
Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier, J. Controlled Release, vol.178, pp.8-17, 2014. ,
Molecular aspects of muco-and bioadhesion:: Tethered structures and sitespecific surfaces, J. Controlled Release, vol.65, issue.1, pp.63-71, 2000. ,
Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa, Int. J. Antimicrob. Agents, vol.27, issue.3, 2006. ,
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis, J. Pediatr, vol.139, issue.4, pp.572-577, 2001. ,
A Method for the High Efficiency of Water-Soluble Carbodiimide-Mediated Amidation, Anal. Biochem, vol.218, issue.1, pp.87-91, 1994. ,
Zero-length crosslinking procedure with the use of active esters, Anal. Biochem, vol.185, issue.1, pp.131-135, 1990. ,
Jr Stability of watersoluble carbodiimides in aqueous solution, Anal. Biochem, vol.184, issue.2, pp.244-248, 1990. ,
Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media, Drug Dev. Ind. Pharm, vol.18, issue.13, pp.123-130, 1992. ,
Validation of quantitative NMR, J. Pharm. Biomed. Anal, vol.38, issue.5, pp.813-823, 2005. ,
Quantitative NMR spectroscopy?applications in drug analysis, J. Pharm. Biomed. Anal, vol.38, issue.5, pp.806-812, 2005. ,
Van Schepdael, A.; Hoogmartens, J. Isolation and structural characterization of colistin components, J. Antibiot, vol.54, issue.7, pp.595-599, 2001. ,
Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis, Antimicrob Agents Ch, vol.43, issue.12, pp.2877-2880, 1999. ,
Aminoglycoside?RNA interactions, Curr. Opin. Chem. Biol, vol.3, issue.6, pp.694-704, 1999. ,
Bacterial biofilms in nature and disease, Annu. Rev. Microbiol, vol.41, issue.1, pp.435-464, 1987. ,
Understanding biofilm resistance to antibacterial agents, Nat. Rev. Drug Discovery, vol.2, issue.2, pp.114-136, 2003. ,